First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion

IntroductionBone and joint infections (BJIs) caused by multidrug-resistant bacteria are becoming more frequent. However, data on the use of novel β-lactam/β-lactamase inhibitors, such as imipenem/cilastatin/relebactam (I-R) and meropenem/vaborbactam (MVB), to treat BJIs is lacking. Furthermore, prol...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Paul Laffont-Lozes, Tayma Naciri, Alix Pantel, Aurélie Martin, Anne-Sophie Pruvot-Occean, Vincent Haignere, Paul Loubet, Albert Sotto, Romaric Larcher
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2024-10-01
سلاسل:	Frontiers in Pharmacology
الموضوعات:	bone and joint infection vertebral osteomyelitis meropenem/vaborbactam continuous infusion imipenem/cilastatin/relebactam extended infusion
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1347306/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!